Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 17936701

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Yang H, et al. (2007) pVHL Acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28, 15-27 17936701

Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.

T531-p - CARD9 (human)

▲

Orthologous residues

CARD9 (human): T531‑p, CARD9 (mouse): T531‑p, CARD9 (rat): T531‑p

Characterization

Methods used to characterize site in vivo: immunoprecipitation, mass spectrometry, phospho-antibody

Relevant cell lines - cell types - tissues: HeLa (cervical), Hep3B (hepatic)

Cellular systems studied: cell lines

Species studied: human

Enzymes shown to modify site in vitro:

Type	Enzyme
KINASE	CK2-A1 (human)

Upstream Regulation

Potential in vivo enzymes for site:

Type	Enzyme	Evidence	Notes
KINASE	CK2-A1 (human)	siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme

Comments: promoted by VHL tumor suppressor protein

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
TBB				decrease

Downstream Regulation

Effect of modification (function): inhibition

Comments: impairs ability of CARD9 to activate NF-kB

T533-p - CARD9 (human)

▲